Pharma giant partners with Durham firm to target sickle cell disease
IMMvention retained rights to use its technology to potentially pursue other targets, such as Parkinson’s or Alzheimer’s ...
Novo Nordisk Inks License Agreement For Sickle Cell Disease Candidate
IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...
Jefferies Keeps Their Buy Rating on Pfizer (PFE)
In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...
Promising Clinical Developments and Strategic Initiatives Drive Buy Rating for Viking Therapeutics
BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...
Bloomberg L.P.19h
Novo Nordisk A/S
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...